Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4760799
Max Phase: Preclinical
Molecular Formula: C33H33ClFN3O4S
Molecular Weight: 622.16
Molecule Type: Unknown
Associated Items:
ID: ALA4760799
Max Phase: Preclinical
Molecular Formula: C33H33ClFN3O4S
Molecular Weight: 622.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N1CCC2(CC1)c1cc(C(=O)NC3(c4ccc(Cl)cc4)CC3)ccc1N(S(=O)(=O)c1ccc(F)cc1)C2C1CC1
Standard InChI: InChI=1S/C33H33ClFN3O4S/c1-21(39)37-18-16-32(17-19-37)28-20-23(31(40)36-33(14-15-33)24-5-7-25(34)8-6-24)4-13-29(28)38(30(32)22-2-3-22)43(41,42)27-11-9-26(35)10-12-27/h4-13,20,22,30H,2-3,14-19H2,1H3,(H,36,40)
Standard InChI Key: SERKEQHWOHIVBT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 622.16 | Molecular Weight (Monoisotopic): 621.1864 | AlogP: 5.77 | #Rotatable Bonds: 6 |
Polar Surface Area: 86.79 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.71 | CX LogD: 4.71 |
Aromatic Rings: 3 | Heavy Atoms: 43 | QED Weighted: 0.38 | Np Likeness Score: -1.06 |
1. Panknin O,Wagenfeld A,Bone W,Bender E,Nowak-Reppel K,Fernández-Montalván AE,Nubbemeyer R,Bäurle S,Ring S,Schmees N,Prien O,Schäfer M,Friedrich C,Zollner TM,Steinmeyer A,Mueller T,Langer G. (2020) Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women., 63 (20): [PMID:32960053] [10.1021/acs.jmedchem.0c01076] |
Source(1):